Drug Profile
Palivizumab biosimilar - Kidswell Bio
Alternative Names: GBS 008Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Gene Techno Science
- Developer Kidswell Bio
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for research development in Respiratory-syncytial-virus-infections in Japan
- 11 Nov 2021 Palivizumab biosimilar - Kidswell Bio is still in early research in Respiratory-syncytial-virus-infections in Japan (Kidswell Bio pipeline, November 2021)
- 28 Aug 2021 No recent reports of development identified for research development in Respiratory-syncytial-virus-infections in Japan